Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 24;24(7):6111. doi: 10.3390/ijms24076111

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Blood cell biomarkers at baseline in bio-naive responders and non-responders treated with either tumor necrosis factor (TNF)-α inhibitors or interleukin (IL)-23/IL-12/23 inhibitors. (A) Neutrophil-to-lymphocyte ratio (NLR). (B) Platelet-to-lymphocyte ratio (PLR). (C) Systemic immune–inflammation index (SII). Responders = psoriasis area and severity index (PASI) ≤ 2 three months after treatment start. Non-responders = PASI > 2 three months after treatment start. ns = non-significant. * p < 0.05.